Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

TNGX

Tango Therapeutics Inc

Nov 14 • 01:10PM ET

8.15

+0.43 5.51 %

Healthcare • Biotechnology • USA • NASD

Peers: CRSP NTLA BEAM KRYS PLRX EDIT SGMO FDMT AFMD VCNX

| Held by: VTI XBI IWM VXF DWAS IWN IBB SCHA VTWO VFMO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.92	Insider Own	41.75%	Shs Outstand	111.57M	Perf Week	3.49%
Market Cap	1.10B	Forward P/E	-	EPS next Y	-1.24	Insider Trans	-5.82%	Shs Float	78.40M	Perf Month	-11.18%
Enterprise Value	977.79M	PEG	-	EPS next Q	-0.31	Inst Own	63.71%	Short Float	37.49%	Perf Quarter	12.81%
Income	-100.52M	P/S	16.49	EPS this Y	27.00%	Inst Trans	16.09%	Short Ratio	10.36	Perf Half Y	443.00%
Sales	66.50M	P/B	5.68	EPS next Y	-42.59%	ROA	-35.74%	Short Interest	29.39M	Perf YTD	163.59%
Book/sh	1.43	P/C	7.15	EPS next 5Y	-5.06%	ROE	-51.65%	52W High	9.70 -16.03%	Perf Year	143.13%
Cash/sh	1.14	P/FCF	-	EPS past 3/5Y	-8.36% 7.47%	ROIC	-52.44%	52W Low	1.03 690.78%	Perf 3Y	7.31%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	4.33% 53.11%	Gross Margin	96.36%	Volatility	9.51% 9.32%	Perf 5Y	-18.55%
Dividend TTM	-	EV/Sales	14.70	EPS Y/Y TTM	21.77%	Oper. Margin	-165.91%	ATR (14)	0.69	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	8.88	Sales Y/Y TTM	53.28%	Profit Margin	-151.15%	RSI (14)	52.49	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	8.88	EPS Q/Q	153.24%	SMA20	1.46%	Beta	1.76	Target Price	12.83
Payout	-	Debt/Eq	0.22	Sales Q/Q	363.61%	SMA50	4.00%	Rel Volume	1.00	Prev Close	7.72
Employees	155	LT Debt/Eq	0.20	Earnings	Nov 04 BMO	SMA200	73.04%	Avg Volume	2.84M	Price	8.15
IPO	Sep 03, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	376.68% 0.02%	Trades		Volume	1,661,026	Change	5.51%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-19-25	Initiated	Piper Sandler	Overweight	$11
Jul-17-24	Initiated	Jefferies	Buy	$19
Apr-04-24	Initiated	Cantor Fitzgerald	Overweight
Feb-12-24	Initiated	Piper Sandler	Overweight	$18
Dec-08-23	Initiated	B. Riley Securities	Buy	$16
Oct-20-22	Upgrade	H.C. Wainwright	Neutral → Buy	$10
Sep-20-21	Initiated	SVB Leerink	Outperform	$25

Nov-12-25 07:00AM	Tango Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference (GlobeNewswire) -8.47%
Nov-04-25 10:15AM	Tango Therapeutics, Inc. (TNGX) Tops Q3 Earnings and Revenue Estimates (Zacks)
09:00AM	Tango Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights (GlobeNewswire)
Nov-03-25 07:46AM	Tango Therapeutics Inc (TNGX) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Oct-31-25 09:55AM	Wall Street Analysts Think Tango Therapeutics (TNGX) Could Surge 52.2%: Read This Before Placing a Bet (Zacks)
07:00AM	Loading…
Oct-29-25 07:00AM	Tango Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 (GlobeNewswire)
Oct-27-25 12:00PM	Tango Therapeutics (TNGX) Upgraded to Buy: Here's Why (Zacks)
Oct-23-25 07:20AM	Tango Therapeutics Announces $225 Million Financing (GlobeNewswire) -13.05%
07:00AM	Tango Therapeutics Reports Positive Data from Ongoing Phase 1/2 Study with Vopimetostat (TNG462) in Patients with MTAP-deleted Cancers (GlobeNewswire)
Oct-06-25 07:00AM	Tango Therapeutics to Present First Clinical Data from TNG260 at Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025 (GlobeNewswire)
Sep-17-25 09:27AM	Tango Therapeutics (TNGX) Soars 7.8%: Is Further Upside Left in the Stock? (Zacks)
Aug-26-25 07:00AM	Tango Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference (GlobeNewswire)
Aug-19-25 09:32AM	Palo Alto upgraded, Li Auto downgraded: Wall Street's top analyst calls (The Fly)
Aug-05-25 08:15AM	Tango Therapeutics, Inc. (TNGX) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights (GlobeNewswire)
09:53AM	Loading…
Aug-04-25 09:53AM	Tango Therapeutics Inc (TNGX) Q2 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Jul-31-25 07:40PM	IGM Biosciences, Inc. (IGMS) Q2 Earnings and Revenues Surpass Estimates (Zacks) +8.11%
Jul-30-25 10:00AM	Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
09:55AM	Wall Street Analysts Believe Tango Therapeutics (TNGX) Could Rally 61.46%: Here's is How to Trade (Zacks)
Jul-29-25 10:00AM	Tango Therapeutics, Inc. (TNGX) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Jul-22-25 07:00AM	Tango Therapeutics to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025 (GlobeNewswire)
Jul-14-25 09:55AM	Does Tango Therapeutics (TNGX) Have the Potential to Rally 75.89% as Wall Street Analysts Expect? (Zacks)
Jun-30-25 05:47AM	Tango doses first subject in MTAP-deleted and RAS mutant cancer trial (Clinical Trials Arena)
Jun-27-25 07:00AM	Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines' Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung Cancer (GlobeNewswire)
Jun-23-25 09:07AM	Tango Therapeutics (TNGX) Moves 7.5% Higher: Will This Strength Last? (Zacks)
May-27-25 07:00AM	Tango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference (GlobeNewswire) +11.41%
May-21-25 07:00AM	Tango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid Tumors (GlobeNewswire) -8.70%
May-12-25 08:15AM	Tango Therapeutics, Inc. (TNGX) Reports Q1 Loss, Lags Revenue Estimates (Zacks) +14.91%
07:00AM	Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights (GlobeNewswire)
May-09-25 09:45AM	Tango Therapeutics Inc (TNGX) Q1 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
08:20AM	Loading…
May-06-25 08:20AM	Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -11.27%
May-05-25 10:00AM	Tango Therapeutics, Inc. (TNGX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks) -5.96%
May-01-25 07:00AM	Tango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 (GlobeNewswire)
Apr-09-25 05:00AM	Barbara Weber, M.D., Elected to ITM Supervisory Board (GlobeNewswire) +16.53%
Mar-25-25 04:30PM	Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline with Five Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025 (GlobeNewswire) -5.75% -6.10%
Feb-27-25 07:00AM	Tango Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Highlights (GlobeNewswire) -6.44%
Feb-20-25 07:30AM	Tango Therapeutics to Present at Three Upcoming Investment Bank Conferences (GlobeNewswire)
Jan-30-25 07:00AM	Tango Therapeutics to Present at the Guggenheim SMID Cap Biotechnology Conference (GlobeNewswire)
Dec-03-24 07:00AM	Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.14%
Nov-27-24 07:00AM	Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference (Business Wire) +6.25%
Nov-23-24 10:26AM	Tango Therapeutics Inc. (TNGX): Among the Most Promising Cancer Stocks According to Hedge Funds (Insider Monkey)
Nov-06-24 07:05AM	Tango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights (Business Wire) -37.45%
07:00AM	Tango Therapeutics Reports Positive TNG462 Clinical Data and Provides Update on PRMT5 Development Program (Business Wire)
Aug-28-24 07:00AM	Tango Therapeutics to Participate in Upcoming Investor Conferences (Business Wire)
Aug-18-24 09:03AM	Jefferies Predicts up to 270% Rally for These 2 Strong Buy Stocks (TipRanks)
Aug-07-24 07:00AM	Tango Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights (Business Wire)
Jun-14-24 05:10AM	Tango Therapeutics (TNGX) Moves 10.3% Higher: Will This Strength Last? (Zacks) +6.44%
Jun-05-24 07:00AM	Tango Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference (Business Wire)
May-23-24 09:18AM	Medivirs licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program (PR Newswire)
07:00AM	Tango Therapeutics Announces Discontinuation of TNG348 Program (Business Wire)
May-08-24 01:53PM	TNGX Stock Earnings: Tango Therapeutics Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:10AM	Tango Therapeutics, Inc. (TNGX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Tango Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights (Business Wire)
May-07-24 10:00AM	Will Tango Therapeutics, Inc. (TNGX) Report Negative Q1 Earnings? What You Should Know (Zacks)
Apr-01-24 04:48PM	Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-20-24 05:31AM	Tango Therapeutics Inc (TNGX) Reports Full Year and Q4 2023 Financial Results (GuruFocus.com)
Mar-18-24 02:52PM	TNGX Stock Earnings: Tango Therapeutics Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace) -7.09%
08:10AM	Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights (Business Wire)
Mar-17-24 05:20PM	11 Oversold Biotech Stocks To Buy Right Now (Insider Monkey)
Mar-06-24 07:00AM	Tango Therapeutics to Participate in Upcoming Investor Conferences (Business Wire)
Mar-05-24 04:47PM	Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024 (GlobeNewswire)
Feb-07-24 08:55AM	Pancreatic Cancer Treatments Poised for Major Advances in 2024 (PR Newswire)
Jan-31-24 07:00AM	Tango Therapeutics to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-05-24 04:05PM	Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-04-24 02:47AM	Medivirs licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study (PR Newswire)
Jan-03-24 07:00AM	Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG348 in Patients with BRCA1/2-Mutant and Other HRD+ Cancers (GlobeNewswire)
Nov-13-23 07:00AM	Tango Therapeutics to Highlight Preclinical Data on PRMT5 Inhibitors at the Society for Neuro-Oncology (SNO) 28th Annual Meeting (GlobeNewswire) -9.45%
Nov-08-23 03:12PM	Tango Therapeutics Inc (TNGX) Reports Q3 2023 Financial Results and Business Updates (GuruFocus.com)
07:00AM	Tango Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Highlights (GlobeNewswire)
Nov-07-23 07:00AM	Tango Therapeutics to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
Oct-10-23 11:28AM	Tango Therapeutics (TNGX) Rises 20% in a Month: Here's Why (Zacks)
Oct-09-23 08:50AM	What Makes Tango Therapeutics, Inc. (TNGX) a Good Fit for 'Trend Investing' (Zacks) -13.27%
Sep-18-23 07:00AM	Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire) +5.88%
Sep-06-23 07:00AM	Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG348, a Novel USP1 Inhibitor for the Treatment of BRCA1/2-mutant and Other HRD+ Cancers (GlobeNewswire)
Sep-05-23 07:00AM	Tango Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-29-23 05:08PM	Tango Therapeutics Announces Updates to Its Board of Directors (GlobeNewswire) -7.51%
Aug-28-23 07:00AM	Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer (GlobeNewswire)
Aug-10-23 07:00AM	Tango Therapeutics Announces $80 million Private Placement Financing (GlobeNewswire) -16.26%
Aug-07-23 07:00AM	Tango Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Highlights (GlobeNewswire)
Jul-24-23 07:00AM	Tango Therapeutics Announces First Patient Dosed in TNG260 Phase 1/2 Trial in Patients With STK11-Mutant Cancers (GlobeNewswire)
Jul-10-23 07:00AM	Tango Therapeutics Announces First Patient Dosed in TNG462 Phase 1/2 Trial in Patients With MTAP-deleted Solid Tumors (GlobeNewswire)
Jun-01-23 07:00AM	Tango Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-09-23 07:00AM	Tango Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Highlights (GlobeNewswire) +6.40%
Apr-18-23 04:30PM	Tango Therapeutics Presents Preclinical Data on Precision Oncology Programs at the American Association of Cancer Research 2023 Annual Meeting (GlobeNewswire) -11.67%
Apr-03-23 07:00AM	Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG260, a First-in-Class CoREST Inhibitor for the Treatment of STK11-Mutant Cancers (GlobeNewswire) +10.38%
Mar-27-23 07:00AM	Tango Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Highlights (GlobeNewswire) -9.35%
Mar-14-23 08:11PM	Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Programs at the American Association of Cancer Research 2023 Annual Meeting (GlobeNewswire)
Mar-10-23 10:15PM	Tango Therapeutics Announces Limited Exposure to Silicon Valley Bank (GlobeNewswire) -13.33% +6.45%
Mar-06-23 07:00AM	Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-01-23 07:00AM	Tango Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-28-23 07:00AM	Tango Therapeutics Announces Appointment of Adam Crystal, M.D., Ph.D. as President of Research and Development (GlobeNewswire) +6.09%
Feb-02-23 07:00AM	Tango Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-25-23 07:00AM	Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG462; Provides Additional Business Updates (GlobeNewswire)
Dec-15-22 07:00AM	HOOKIPA Pharma Appoints Katia Schlienger, M.D., Ph.D., Chief Medical Officer and Malte Peters, M.D., to Board of Directors (GlobeNewswire)
Nov-10-22 07:00AM	Tango Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Highlights (GlobeNewswire) -5.27%
Nov-07-22 07:00AM	Tango Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-19-22 07:00AM	Tango Therapeutics Announces Presentation of Preclinical Data on PRMT5 Inhibitors TNG908 and TNG462 in Three Abstracts Accepted at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Oct-05-22 08:10AM	Tango Therapeutics Announces Presentation of Preclinical Data on TNG260 and Discovery Platform Advances at SITC 37th Annual Meeting (GlobeNewswire)
Sep-06-22 07:00AM	Tango Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire) -12.62%

Tango Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in discovering and delivering precision cancer medicines. It also identifies novel targets and develops new drugs directed at tumor suppressor gene loss in defined patient populations with high unmet medical need. The company was founded by Alan Ashworth, William G. Kaelin Jr., Jose Baselga, and Antoni Ribas in 2017 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Third Rock Ventures IV, L.P.	10% Owner	Oct 23 '25	Sale	10.15	477,401	4,846,575	13,386,574	Oct 27 04:15 PM
Third Rock Ventures IV, L.P.	10% Owner	Oct 23 '25	Proposed Sale	7.53	477,401	3,594,830		Oct 23 05:10 PM
Third Rock Ventures IV, L.P.	10% Owner	Sep 25 '25	Sale	8.02	500,000	4,008,500	13,863,975	Sep 29 04:15 PM
Third Rock Ventures IV, L.P.	10% Owner	Sep 25 '25	Proposed Sale	7.80	500,000	3,900,000		Sep 25 04:58 PM
Third Rock Ventures IV, L.P.	10% Owner	Sep 16 '25	Sale	7.04	363,541	2,559,329	14,363,975	Sep 17 06:06 PM
Third Rock Ventures IV, L.P.	10% Owner	Sep 16 '25	Proposed Sale	7.35	363,541	2,672,026		Sep 17 10:29 AM
Third Rock Ventures IV, L.P.	10% Owner	Sep 05 '25	Sale	7.00	642,906	4,500,342	14,813,975	Sep 09 04:15 PM
Third Rock Ventures IV, L.P.	10% Owner	Sep 08 '25	Sale	7.04	86,459	608,628	14,727,516	Sep 09 04:15 PM
Third Rock Ventures IV, L.P.	10% Owner	Sep 08 '25	Proposed Sale	7.04	86,459	608,628		Sep 08 05:22 PM
Third Rock Ventures IV, L.P.	10% Owner	Sep 05 '25	Proposed Sale	6.94	642,906	4,461,767		Sep 05 06:08 PM
Third Rock Ventures IV, L.P.	10% Owner	Aug 22 '25	Sale	7.00	302,194	2,115,358	15,456,881	Aug 26 04:15 PM
Third Rock Ventures IV, L.P.	10% Owner	Aug 22 '25	Proposed Sale	6.90	302,194	2,085,139		Aug 22 05:26 PM
Third Rock Ventures IV, L.P.	10% Owner	Aug 19 '25	Sale	7.01	1,100,000	7,712,760	15,759,075	Aug 21 04:15 PM
Third Rock Ventures IV, L.P.	10% Owner	Aug 19 '25	Proposed Sale	6.96	1,100,000	7,656,000		Aug 19 07:25 PM
Barry Douglas	General Counsel	Feb 04 '25	Sale	2.99	2,774	8,289	68,570	Feb 06 08:21 PM
Barry Douglas	General Counsel	Feb 05 '25	Sale	3.16	2,556	8,081	66,014	Feb 06 08:21 PM
Beckman Daniella	Chief Financial Officer	Feb 04 '25	Sale	2.99	4,284	12,801	154,232	Feb 06 08:10 PM
Beckman Daniella	Chief Financial Officer	Feb 05 '25	Sale	3.16	3,948	12,481	150,284	Feb 06 08:10 PM
Crystal Adam	See Remarks	Feb 04 '25	Sale	2.99	7,432	22,207	165,061	Feb 06 08:08 PM
Crystal Adam	See Remarks	Feb 05 '25	Sale	3.16	6,851	21,659	158,210	Feb 06 08:08 PM
Weber Barbara	Chief Executive Officer	Feb 04 '25	Sale	2.99	9,778	29,217	1,631,264	Feb 06 08:02 PM
Weber Barbara	Chief Executive Officer	Feb 05 '25	Sale	3.16	9,013	28,494	1,622,251	Feb 06 08:02 PM
Rothenberg Mace	Director	Nov 18 '24	Buy	3.78	10,000	37,800	31,250	Nov 18 07:20 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TNGX

Tango Therapeutics Inc

Upgrade your FINVIZ experience